# Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects

> **NCT00144833** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 150 (estimated)

## Conditions studied

- HIV-1

## Interventions

- **DRUG:** fosamprenavir/ritonavir (700mg/100mg BID)
- **DRUG:** fosamprenavir/ritonavir (1400mg/100mg BID)
- **DRUG:** fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)

## Key facts

- **NCT ID:** NCT00144833
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-03
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 150 (ESTIMATED)
- **Why stopped:** Incomplete data
- **Last updated:** 2007-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00144833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00144833, "Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00144833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*